Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

Nature

Volumn 514, Issue 7520, 2015, Pages 112-116

  Tavora, Bernardo ^a   Reynolds, Louise E ^a   Batista, Silvia ^a   Demircioglu, Fevzi ^a   Fernandez, Isabelle ^a   Lechertier, Tanguy ^a   Lees, Delphine M ^a   Wong, Ping Pui ^a   Alexopoulou, Annika ^a   Elia, George ^a   Clear, Andrew ^a   Ledoux, Adeline ^b   Hunter, Jill ^b   Perkins, Neil ^b   Gribben, John G ^a   Hodivala Dilke, Kairbaan M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FOCAL ADHESION KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; CYTOKINE;

AMINO ACID; APOPTOSIS; BLOOD; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DNA; ENZYME; GENE EXPRESSION; MOLECULAR ANALYSIS; RODENT; SENSITIVITY ANALYSIS; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DNA DAMAGE; ENDOTHELIUM CELL; ENZYME SPECIFICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR REGRESSION; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; RADIATION EXPOSURE;

MUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; CELL NUCLEUS; CELL PROLIFERATION; CYTOKINES; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MICE; NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION;

EID: 84906937038     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13541     Document Type: Article

References (30)

1. De Vita, V. T., Hellman, S. & Rosenberg S. A. Cancer: Principles and Practice of Oncology (Lippincott Williams and Wilkins, 2001).
2. Rottenberg, S. & Jonkers, J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updat. 11, 51-60 (2008).
3. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
4. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
5. Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Med. 18, 1359-1368 (2012).
6. Nakasone, E. S. et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
7. Gilbert, L. A. & Hemann, M. T. DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366 (2010).
8. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012).
9. Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171-185 (2013).
10. Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516-523 (2006).
11. Lim, S. T. et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J. Cell Biol. 197, 907-919 (2012).
12. McLean, G. W. et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 18, 2998-3003 (2004).
13. Shibue, T.& Weinberg, R. A. Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290-10295 (2009).
14. Tavora, B. et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med. 2, 516-528 (2010).
15. Nakamura, J. et al. Biphasic function of focal adhesion kinase in endothelial tube formation induced by fibril-forming collagens. Biochem. Biophys. Res. Commun. 374, 699-703 (2008).
16. Stokes, J. B. et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 10, 2135-2145 (2011).
17. Fisher, R. I. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328, 1002-1006 (1993).
18. Hagemeister, F. B. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother. Pharmacol. 49 (suppl. 1), 13-20 (2002).
19. Hambardzumyan, D. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436-448 (2008).
20. Perkins, N. D. The diverse and complex roles of NF-κB subunits in cancer. Nature Rev. Cancer 12, 121-132 (2012).
21. Zhang, H. M. et al. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-κB signaling in intestinal epithelial cells. Am. J. Physiol. Cell Physiol. 290, C1310-C1320 (2006).
22. Tseng, W. P., Su, C. M. & Tang, C. H. FAK activation is required for TNF-α-induced IL-6 production in myoblasts. J. Cell. Physiol. 223, 389-396 (2010).
23. Petzold, T. et al. Focal adhesion kinase modulates activation of NF-κB by flow in endothelial cells. Am. J. Physiol. Cell Physiol. 297, C814-C822 (2009).
24. Funakoshi-Tago, M. et al. Tumor necrosis factor-induced nuclear factor κB activation is impaired in focal adhesion kinase-deficient fibroblasts. J. Biol. Chem. 278, 29359-29365 (2003).
25. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunol. 12, 715-723 (2011).
26. DiDonato, J. A., Mercurio, F. & Karin, M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400 (2012).
27. Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammationassociated cancer. Nature 431, 461-466 (2004).
28. Reynolds, L. E. & Hodivala-Dilke, K. M. Primary mouse endothelial cell culture for assays of angiogenesis. Methods Mol. Med. 120, 503-509 (2006).
29. May, T. et al. Establishment of murine cell lines by constitutive and conditional immortalization. J. Biotechnol. 120, 99-110 (2005).
30. Rocha, S., Campbell, K. J. & Perkins, N.D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12, 15-25 (2003).